Park Medi World Q2 FY27 Earnings Call: Guides 40% Bed Expansion in FY27, New-Unit Margin Drag to Ease (PARKHOSPS)

Strong top line, but margins compressed by new-unit drag and cost step-up

• Q2 FY 2026-2027 revenue of Rs.511 crore — up 25% YoY from Rs.410 crore in Q2 FY 2025-2026, driven by steady patient volumes and ramp-up at newer and recently acquired hospitals.
• Q2 operating EBITDA (ex-other income) of Rs.102 crore — a 19.9-20% margin; PAT was Rs.54.5 crore at an 10.7-11% margin.
• H1 FY 2026-2027 revenue of Rs.987 crore — up 22% YoY from Rs.809 crore; H1 EBITDA ex-other income was Rs.228 crore (23.1% margin, +5% YoY) and PAT Rs.143 crore (14.5% margin).
• Record 5.39 lakh patients served in H1 FY 2026-2027 — the company's highest-ever half-yearly revenue from operations.
• 14 established hospitals (ex-Agra, Panchkula, Rudrapur) delivered 26% EBITDA and 17% PAT margins in H1 FY 2026-2027, versus the blended 23.1% EBITDA margin.
• Balance sheet as of 30 September 2026 — term debt ex-lease liabilities of Rs.178 crore, fixed deposits of Rs.325 crore; net worth rose from Rs.1,196 crore (H1 FY 2025-2026) to Rs.2,164 crore (H1 FY 2026-2027).

Double-digit volume growth; occupancy dilutes on capacity step-up

• IPD volume up 31% YoY to 31,000 patients in Q2 FY 2026-2027; OPD up 29% to 2,59,000 patients.
• ARPOB up 13% YoY to ~Rs.30,646 in Q2 FY 2026-2027 from Rs.27,007 in Q2 FY 2025-2026; ALOS improved 14% to 5.4 days from 6.3 days.
• H1 FY 2026-2027 — IPD and OPD each grew 23% YoY to 57,000 and 4,82,000 patients; ARPOB rose 13% to Rs.30,548; ALOS improved 11% to 5.6 days.
• High-end specialties contributed ~64% of Q2 FY 2026-2027 revenue — up 730 bps YoY (~63% in H1, up 640 bps); transplant, interventional cardiology and robot-assisted joint replacement programs continued to scale.
• Network occupancy fell to 56% in Q2 and H1 FY 2026-2027 from 60% and 68% a year earlier; the CEO attributed the decline mainly to a capacity step-up of 1,040 beds added across the new Agra, Panchkula and Rudrapur units over the past 12 months.
• Doctor headcount rose by 232 — from 1,168 to 1,400 within H1 FY 2026-2027 (dates as spoken on the call).

Material and F&B inflation; new hospitals at -8% EBITDA

• Three FY 2026-2027 hospitals (Rudrapur, Agra, Panchkula) generated Rs.72 crore H1 revenue at ~-8% EBITDA margin — a Rs.6 crore hit versus the Rs.234 crore EBITDA of the 14 established hospitals (Rs.915 crore revenue at 26% margin).
• Cost of material consumed rose from Rs.70 crore to Rs.116 crore in Q2 FY 2026-2027 vs Q2 FY 2025-2026 (CEO cited the base as Rs.77 crore, figures as spoken); ~Rs.8 crore was a one-time F&B step-up (meal cost Rs.270 → Rs.400, ~50%, not passed through), with the remaining ~Rs.31 crore from margin-dilutive medicines, antibiotics and implants (~Rs.2 crore per hospital for the six-month period).
• Other expenses rose to 23% of revenue in FY 2026-2027 from 21% in FY 2025-2026 — the CEO described the 2% gap as roughly flat, attributing the absolute rise to ~23-24% revenue growth.
• CEO called the Rs.39 crore Q2 cost increase "judicious" — a one-time step-up in preparation for future growth; he expects ARPOB gains to align costs with revenue, with the margin impact streamlining in Q3 FY 2026-2027.
• New units expected EBITDA-positive within ~12 months — reaching the ~26% blended margin in roughly 3 to 3.5 years; insurance empanelment, which typically takes time, is a factor in the ramp. Analyst Anshul Agarwal (MK Global) estimated the drag at ~Rs.30 crore and 300 bps of H1 margin contraction.
• Claims disallowed rose to 13.5% in Q2 FY 2026-2027 from 11% a year earlier; the CFO expects a return to the prior-year level by end of FY 2026-2027. The CFO deferred the question on the deferred tax benefit reversal and resulting Q2 tax rate increase, saying it would be explained separately.

Receivable days spike to 160; management expects normalisation by March 2027

• Receivable days stood at 160 as of 30 September 2026 — consolidated debtors of Rs.871 crore, or ~Rs.815 crore excluding ~Rs.45 crore of debtors from the Agra and Rudrapur acquisitions.
• Seasonal timing cited — payments expected in September arrived in October; receivable days were 135-136 as of 31 October 2026, and the CEO expects annualized consolidated receivable days of 125-130 as of 31 March 2027.
• CFO guided receivable days below 130 by the close of FY 2026-2027 — acquired-entity receivables relate to government schemes and TPA payers; under the SPA, pre-acquisition receivables are realized on an actual basis and passed on to the sellers while remaining on the books.
• 1,66,742 operational bed days lost in Q2 FY 2026-2027, per the Group CFO.

Government insurance dominates revenue; oncology capping called negligible

• Government insurance schemes contributed ~76% of Q2 FY 2026-2027 revenue — self-pay and TPA private insurance contributed 24%; management said the mix is gradually shifting toward the 70:70:30 split it guided to over the next 12 to 18 months.
• CEO said the oncology price capping implication for Park is "negligible" — ESI and CGHS beneficiaries buy medicines from government infrastructure, so Park treats these patients but does not sell them medicine; under ECHS contractual arrangements, A-grade hospitals must give a discount of almost 30%, and reaching 26% EBITDA after that requires procurement efficiency of about 36-38%, so premium capping does not apply to Park's business.
• CGHS rate hike (announced October 2025, covering an estimated 5,500-6,000 line items per the speaker) — Sharma said Park was expected to be the largest beneficiary, with about 95-98% of the hike already factored into current operations; about 7 months of FY 2026-2027 are applicable at 95-97% of the hike.
• Effective CGHS impact of ~6% on revenue — the hike is ~10% on operational income; ~75% of FY 2026-2027 revenue guidance (~Rs.2,050 crore) comes from government insurers, of which 92% are benchmarked to CGHS rates. Applied to the FY 2025-2026 top line of ~Rs.1,680 crore, that is ~Rs.85-90 crore full-year, or ~Rs.58-60 crore for the seven months of FY 2026-2027.

40% bed expansion in FY27; Rs.750 crore capex pipeline to December 2028

• FY 2026-2027 guidance reiterated — revenue close to Rs.2,050 crore and PAT of about Rs.540-550 crore.
• 1,430 incremental beds guided for FY 2026-2027 (+40%) — 680 beds already commissioned across Panchkula and Rudrapur, with a further 750 expected over the rest of FY27; for FY 2027-2028, the company is looking at a 1,000-bed expansion across four hospitals.
• 2,300 beds under execution, operational by December 2028 (Q3 FY 2028-2029) — ~Rs.750 crore capex at ~Rs.33.5 lakh per bed, taking capacity from 4,290 beds (30 September 2026) to 6,590 beds, a 54% increase; capex per bed expected within Rs.30-35 lakh for these beds. Note: the CFO separately cited total bed capacity of 6,590 to be added by December 2028, which conflicts with the CEO's 2,300 figure, both as spoken.
• Blended capex per operating bed of Rs.36-38 lakh "all the way till 2028" per the CEO, when capacity reaches 6,600 beds; current capex per bed is ~Rs.35 lakh (CFO: lowest among listed healthcare peers). The Allahabad 550-bed hospital has Rs.210 crore capex provision, of which Rs.85 crore will be reimbursed by government, with commissioning expected October-November 2028 at ~Rs.25 lakh per bed net of reimbursement.
• FY 2027-2028 top line guided to close to Rs.2,550 crore — with ~20% expected from newly added hospitals and ~10-12% of EBITDA from them in FY 2027-2028.
• B3 Healthcare (80% stake, university hospital in Rudrapur) began operations 1 August FY 2026-2027 and is EBITDA positive — run rate ~Rs.5 crore/month, expected to reach Rs.7.5 crore/month in December (FY 2026-2027) and more than Rs.10 crore/month by April 2027 (FY 2027-2028); the company is committed to acquiring the remaining 20% by close of FY 2026-2027 or at the latest Q1 FY 2027-2028, to own 100%.
• Break-even cadence — brownfield assets historically reach operating break-even in 4-6 months at 30-35% occupancy (Batinda, started July 2025 in FY 2025-2026, was PAT positive in its first month; Dudrapur roughly EBITDA positive in its first month); greenfield hospitals take ~12-15 months and have taken about 4 years to reach ~70% occupancy. Ongoing expansion is "creating a little drag" on occupancy while hospitals mature.